Introduction
Chronic hepatitis C virus (HCV) infection is a leading cause of chronic liver disease in Australia, representing a substantial burden in terms of morbidity, mortality, and costs. In 2012, the number of people living with chronic HCV infection in Australia was estimated to be 231,500 [1] and approximately 55% of these are infected with genotype 1 [2] . The virus is transmitted by blood-to-blood contact and reproduces within hepatic cells. Over time, the endless cycle of viral reproduction results in significant damage to the patient's liver. Unlike hepatitis A or B, there is no vaccine for HCV. Successful treatment, however, can result in a cure (sustained virological response [SVR] ) by elimination of the virus.
Telaprevir (Incivo), a selective HCV NS3/4A serine protease inhibitor, has been reimbursed through the Pharmaceutical Benefits Scheme (PBS) since April 2013. Clinical trials [3, 4] have demonstrated that telaprevir in combination with pegylated interferon and ribavirin (PR) is superior to PR alone (the previous standard of care) in patients with genotype 1 chronic HCV infection (i.e., telaprevir plus PR generates significantly more SVRs than does PR alone). Furthermore, the use of telaprevir plus PR in a previously untreated patient can reduce the duration of coadministered PR therapy. This is because patients without cirrhosis on telaprevir who achieve an extended rapid viral response (defined as achieving undetectable HCV RNA levels at weeks 4 and 12) can reduce their duration of PR therapy to 24 weeks instead of requiring a 48-week course.
There are four recently published economic evaluations of telaprevir, three of which are performed either in the treatmentnaive setting [5] or in the treatment-experienced setting [6, 7] . Only one previous evaluation [8] has used the same model structure to estimate the cost-effectiveness of telaprevir in both treatment settings. The objective of our study was to calculate the incremental cost-effectiveness ratio (ICER) of telaprevir plus PR compared with PR alone in an Australian setting in both patients who are naive to treatment and those who have previously failed treatment with PR (treatment-experienced patients). As a result, our study not only uses the same model to estimate the costeffectiveness of telaprevir in both treatment settings but also incorporates the revised categorization of SVR accepted by the Australian regulatory authority (Therapeutic Goods Administration), and the stopping rules for telaprevir and PR that are consistent with the PBS reimbursement criteria for these therapies.
Methods

Model Structure
The model has two components (Fig. 1) . The first year of the model (in which patients are receiving HCV treatment) is modeled as a trial-based decision tree. After receiving antiviral treatment in the setting of mild (no or minimal), moderate (portal or bridging), or severe (compensated cirrhosis) fibrosis, patients can either achieve an SVR or not. In the second year, depending on their SVR status after treatment, patients enter the long-term Markov structure that was used to simulate the natural history of HCV infection over a 60-year (lifetime) time horizon with annual Markov cycles. Similar to other published economic models of telaprevir [5, 7] , the following health states were incorporated into the Markov model: SVR after mild or moderate fibrosis, SVR after cirrhotic disease, mild HCV (no SVR), moderate HCV (no SVR), compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma (HCC), liver transplant (first year), post-liver transplant (subsequent years), and death (Fig. 1) . As a result of the improved SVR rate, fewer patients treated with telaprevir plus PR experienced disease progression to liver failure, HCC, or liver transplant than did patients treated with PR alone, with each of these events associated with an increased probability of death. At a request of the Australian Pharmaceutical Benefits Advisory Committee, the model assumes that 1.8% of the patients with an SVR are reinfected with HCV at 2 years (based on a study of 395 subjects Fig. 1 -Markov model structure. Every year, patients can move between heath states according to a defined transition probability. Note. Age standardised, all cause mortality was also included from the more severe health states such as decompensated cirrhosis and HCC, but has been excluded from this diagram for clarity. HCC, hepatocellular carcinoma; HCV, hepatitis C virus; SVR, sustained virological response.
with SVR [9] ). Reinfected individuals return to the fibrosis health state that they occupied before achieving their SVR (i.e., mild HCV, moderate HCV, or cirrhosis) because retreatment is not incorporated and experience the same degree of disease progression as do those who did not achieve an SVR. Costs are analyzed using an Australian government perspective (2014 prices) and include drug costs, patient monitoring costs, costs associated with treating telaprevir-induced adverse events, and savings associated with avoided future hepatic events. Future years' costs and qualityadjusted life-years (QALYs) were discounted by 5% in accordance with Australian guidelines. The model was developed in Microsoft Excel (Microsoft Corporation, Redmond, WA).
Patient Cohort and Demographic Characteristics
The model was constructed to compare the cost-effectiveness of telaprevir in two populations: 1) previously untreated patients (treatment naive) and 2) patients who had received treatment with PR earlier (treatment experienced). Consistent with PBS reimbursement of telaprevir in Australia, patients with HCV infection with mild fibrosis, moderate fibrosis, or compensated cirrhosis are eligible for telaprevir treatment.
The patient population in the treatment-naive model is based on the ADVANCE study (age 49 years, 58.7% men, 38.8% with mild HCV, 55.4% with moderate HCV, and 5.8% with compensated cirrhosis at baseline) [3] . The patient population in the treatment-experienced model is based on the REALIZE study [4] (age 51 years, 68.6% men, 21.6% with mild HCV, 52.8% with moderate HCV, and 25.6% with compensated cirrhosis at baseline), in which all subjects had failed at least one course of PR therapy. The ADVANCE and REALIZE trials are broadly representative of Australian patients with genotype 1 chronic HCV infection.
Comparative Efficacy of Telaprevir
SVR rates (defined as undetectable HCV RNA levels 24 weeks after the completion of therapy) used in the model are presented in Table 1 . The SVR rates were calculated from the individual patient data from the ADVANCE [3] and REALIZE [4] studies. The revised categorization of SVR (used in both the Therapeutic Goods Administration-approved Australian Product Informations for telaprevir [10] and boceprevir [11] ), however, differs slightly from the methodology used in the ADVANCE [3] and REALIZE [4] publications, with regard to the handling of missing data 24 weeks after the completion of therapy, and use of a HCV RNA quantification level of less than 25 IU/mL, as accepted by regulatory authorities.
Disease Progression
During each annual Markov cycle, patients remain in their current health state, progress to the next more severe health state, or die. Markov transition probabilities were taken from Australian-specific sources where possible. Where Australianspecific data were not available, transition probabilities were taken from the published literature [1, [12] [13] [14] [15] [16] [17] [18] [19] [20] . The probability of receiving a liver transplant is country-specific. The annual probability of receiving a liver transplant for patients with HCC has been calculated by dividing the number of liver transplants due to HCC (12 transplants) by the total number of patients with HCC in the same year (132 patients) [1] . The annual probability of a liver transplant in patients with decompensated cirrhosis has been taken from the Australian budget impact model conducted by the Kirby Institute [16] . The annual probability of death due to HCC has been estimated using the 5-year survival rates reported in New South Wales and Victoria [18, 19] , the two most populous states in Australia. An average of the 5-year survival rates reported in New South Wales and Victoria (15.2%) has been converted into an annual probability (0.314) using the formula P ¼ 1 -exp Àr , where P is the annual probability and r is the annual rate of death. Data from the Australian and New Zealand Liver Transplant Registry have been used to determine the probability of death after transplant, which is significantly greater in the first year after the transplant than in subsequent years. Australian data suggest that posttransplant survival rates are 89% and 71% at 1 and 10 years, respectively [17] . Thus, the estimated annual probability of death during the first year after transplant is 0.110. The estimated annual probability of death during subsequent years is 0.022. Table 2 presents the Markov transition probabilities used in the model. Not all the published economic models permit treatment of patients with HCV infection with cirrhosis (i.e., the treated population is restricted to those with mild or moderate HCV infection). However, in many of the published models that do include patients with cirrhosis in the treated population [21] [22] [23] , patients achieving an SVR are considered to be "cured" of their virus irrespective of their fibrosis status before treatment. Some of the more recent evaluations [7, 24] , however, incorporate disease progression to HCC for patients with cirrhosis who achieve an SVR. Consistent with this more recent methodology, this telaprevir economic model assumes that patients with cirrhosis who achieve an SVR after treatment experience some degree of disease progression to HCC ( Table 2 ). The probability of developing HCC in patients who do not achieve an SVR is taken from a longitudinal study of 384 patients [15] . The odds ratio of progression to HCC in patients achieving an SVR compared with those not achieving an SVR is 0.4 [20] . Therefore, the annual probability of developing HCC in patients with cirrhosis who achieved an SVR is 0.006 (¼ 0.015 Â 0.4). Furthermore, the evaluation performed by Chhatwal et al. [24] also incorporates progression to decompensated cirrhosis for patients with cirrhosis who achieved an SVR. Consistent with most of the published models and Australian clinical advice, the base case of this telaprevir model assumes no progression to decompensated cirrhosis in those who achieved an SVR. This Note. The total number of SVRs in the model is identical to the TGA-approved Australian Product Information [10] . However, in the model, mild HCV consists of no or minimal fibrosis and moderate HCV consists of portal or bridging fibrosis. HCV, hepatitis C virus; PR, pegylated interferon plus ribavirin; SVR, sustained virological response; TGA, Therapeutic Goods Administration.
assumption, however, was tested in sensitivity analyses. Age-and sex-standardized all-cause mortality rates were obtained from Australian life tables [25] . Table 3 presents the unit costs used in the model. The cost of 6-week treatment with telaprevir in Australia is AU $14,866 [26] . Consistent with the PBS reimbursement criterion for telaprevir, the model assumed that only those patients whose plasma HCV RNA level is less than 1000 IU/mL at the week-4 assessment receive the full 12-week course of telaprevir [26] . The model also assumed that patients who discontinued telaprevir treatment in the ADVANCE [3] and REALIZE [4] trials because of adverse events were dispensed 6 weeks of telaprevir treatment (because one prescription provides patients with 6 weeks of supply). The average duration of telaprevir therapy is estimated to be 11.3 weeks in the treatment-naive setting and 11.1 weeks in the treatment-experienced setting.
Costs of Treatment
The cost of 8-week treatment with PR in Australia is AU $3406 [26] . The duration (and hence cost) of PR treatment in both arms of the model is consistent with the PBS reimbursement criteria for PR [26] . The model assumed that patients who discontinued PR because of adverse events [3, 4] were dispensed 8 weeks of PR treatment (because one prescription provides 8 weeks of supply). In the treatment-naive setting, the average duration of PR treatment is estimated to be 27.6 weeks when coadministered with telaprevir and 39.9 weeks when administered alone. In this setting, the average duration of PR treatment is shorter when administered with telaprevir. This is because treatment-naive patients without cirrhosis on telaprevir who achieve an extended rapid viral response can reduce their duration of PR therapy to 24 weeks instead of requiring a 48-week course. Approximately 60% of the patients who receive telaprevir plus PR in the treatmentnaive setting would be able to reduce their duration of PR to 24 weeks. In the treatment-experienced setting, the average duration of PR when given with telaprevir is 32.3 weeks and only 21.5 weeks when given alone. In this setting, the average duration of PR treatment is shorter when administered without telaprevir because patients are discontinuing PR therapy because of lack of effect.
Costs of Monitoring
As given in Table 3 , all unit costs for pathology, clinician visits, and HCV RNA level monitoring are taken from the Australian Medicare Benefits Schedule [27] . It is assumed that patients underwent pathology screening (full blood cell count, liver function, prothrombin time, and thyroid function) before the commencement of antiviral treatment. Patients receiving telaprevir plus PR are assumed to visit the specialist at baseline, at weeks 4, 6, and 12, and for an assessment of SVR status 24 weeks after completing treatment. Patients treated with PR alone undergo a similar schedule of physician visits but omit visits at weeks 4 and 6. Nurse visits for both treatment arms occur at weeks 4, 12, and 24 (if the patient is still on treatment) and at end of treatment. For patients on telaprevir plus PR, quantitative HCV RNA assays are conducted at baseline and week 4 (to determine whether the patient's plasma HCV RNA level is o1000 IU/mL), and qualitative HCV RNA assays are conducted at week 12, end of treatment (if after week 12), and at assessment of SVR status (24 weeks after the last dose of treatment). Patients treated with PR alone undergo a similar schedule of HCV RNA testing; however, the quantitative assay is conducted at week 12 (instead of week 4) to determine whether the patient fulfils the criteria for continuing PBS-subsidized PR treatment.
Costs Associated with Telaprevir-Induced Adverse Events
The model incorporated the cost of telaprevir-induced anemia and rash. The incidence of these adverse events was taken from the ADVANCE and REALIZE trials [3, 4] . The telaprevir Product Information recommends reducing the ribavirin dose in patients experiencing anemia [10] . Consistent with Blazquez-Perez and San Miguel [5] , patients experiencing anemia were assumed to incur the cost of two visits to their specialist and two blood cell count tests. All patients experiencing rash incurred the cost of one GP visit and betamethasone steroid cream. In addition, patients experiencing rash at a grade 3 severity level or above were assumed to visit their specialist and patients whose rash was graded as serious incurred the cost of treatment in hospital [28] .
Costs Associated with HCV
With respect to the annual cost of each Markov health state, the same methodology was applied as was used in a previous Australian economic model [29] . In the Shiell et al. [29] model, the resources used in each health state were based on clinical protocols as specified by the National Health and Medical Research Council and the clinical opinion of one of the authors (Director of Gastroenterology and Hepatology at The Canberra Hospital). The type and quantity of resource used in each health state have been taken from Shiell et al. [29] (because more recent information is not available). The unit cost for these resources was updated using 2014 cost data from the Medicare Benefits Schedule and Australian national diagnosis related groups for 
hospital admissions [27, 28] . The annual cost associated with each health state is given in Table 4 .
Quality of Life
A utility value was associated with each health state to assess quality of life. Utility scores for the first year of the model (in which patients are receiving HCV treatment) are taken directly from the three-level EuroQol five-dimensional questionnaire data collected in the ADVANCE and REALIZE studies [3, 4] (because this takes into account the utility gains associated with a reduced duration of PR therapy in patients who achieve an extended rapid viral response, and the disutility associated with adverse events), using the UK algorithm [30] to assign an index value to each EuroQol five-dimensional questionnaire health state. During the first year, treatment-naive patients receiving telaprevir plus PR have a mean utility of 0.797 and patients treated with PR alone have a mean utility of 0.782 [31] .
In the treatment-experienced setting, patients receiving telaprevir plus PR have a mean utility of 0.695 and patients treated with PR alone have a mean utility of 0.710 [32] . Given that PR therapy is associated with psychological adverse events (such as insomnia, depression, and anxiety), it is reasonable that shortening the duration of PR treatment in treatment-naive patients results in a small utility gain. Utility values for Markov health states have been taken from Wright et al. [33] because these were obtained via the EuroQol five-dimensional questionnaire (which was also used in the telaprevir studies [3, 4] ). The model reported in Wright et al. [33] was constructed on behalf of the National Institute for Health and Care Excellence in the United Kingdom. Patients infected with genotype 1 chronic HCV infection live a reduced quality of life, commonly experiencing fatigue, irritability, depression, loss of appetite, abdominal pain, muscle aches, and fever as well as discrimination and stigma about their disease. Therefore, it follows that utility values in patients who achieve an SVR are typically higher than in those who have not achieved an SVR. Table 4 presents the utility value for each health state in the Markov model.
Model Validation
Internal validity was assessed through routine "debugging" (i.e., setting identical SVR rates for both treatment arms, eliminating disease-specific mortality, and setting utility weights to 1). With regard to external validation, we projected the incidence of liverrelated complications (compensated cirrhosis, decompensated cirrhosis, and HCC) for comparison with other studies. The treatment-naive model predicted a 20-year risk of 28% of developing compensated cirrhosis in the PR-alone arm. This result is slightly higher than the 25% risk for the PR treatment arm reported in Siebert et al. [34] , the overestimation in our model most likely due to the reincorporation of patients with SVR who become reinfected. The telaprevir model by Blazquez-Perez and San Miguel [5] estimated that 21% of the patients have progressed to cirrhosis at 20 years. For comparison, if the baseline fibrosis status is amended to be the same as Blazquez-Perez and San Miguel [5] (mild 80%, moderate 14%, cirrhosis 6%), the Markov model predicted a 20-year risk of 17% of developing compensated cirrhosis, highlighting the importance of sensitivity analyses around the baseline fibrosis status of patients. Our base-case model, however, predicted 20-year risks for decompensated cirrhosis (10% in our model vs. 11% in Siebert et al. [34] ) and HCC (4.5% in our model vs. 4.7% in Siebert et al. [34] ) that are consistent with other studies [34] . AR-DRG, Australian refined diagnostic related group; GP, general practice; HCV, hepatitis C virus; MBS, Medicare Benefits Scheme; PBS, Pharmaceutical Benefits Scheme; PR, pegylated interferon plus ribavirin; RNA, ribonucleic acid.
Our telaprevir model consists of 11 Markov health states, 3 of which relate to the severity of the disease (mild fibrosis, moderate fibrosis, and compensated cirrhosis). The published model constructed by the Australian Kirby Institute [16] has five Markov health states relating to the severity of the HCV infection (F0, F1, F2, F3, and cirrhosis). To validate the results generated in the telaprevir model, an adaptation was performed in which our model was adapted to incorporate five fibrosis health states. The telaprevir three-state fibrosis model generated similar estimates of incidence of cirrhosis as did the model using five fibrosis states. Thus, the telaprevir economic model is consistent with the Kirby Institute model at predicting downstream health states.
Sensitivity Analysis
Univariate sensitivity analyses were performed on parameter values to determine the impact on ICERs, including discount rate (0% and 3.5% for both costs and benefits), fibrosis status of patients at baseline, SVR rates, transition probabilities, utility values, health state costs, and background mortality. Consistent with a small number of published evaluations [20, 24] , we examined the impact of assuming that patients with cirrhosis who achieve an SVR experience progression to decompensated cirrhosis (in addition to HCC), with an annual transition probability of 0.0125 [20] . Several of the most recently published evaluations have introduced higher non-liver-related mortality in patients with chronic HCV infection compared with the general population [5, 8, 35] . We conducted a sensitivity in which age-and sex-standardized all-cause mortality rates for the entire modeled population were 2.34 times [36] that obtained from the Australian life tables (i.e., patients with SVR also incur the increased risk of non-liver-related mortality). In addition, because probabilistic sensitivity analysis is not required for reimbursement in Australia, multivariate sensitivity analyses were conducted combining the variables shown to be sensitive in the univariate analyses.
Results
Base-Case Analysis
Using a cohort of 1000 patients in the treatment-naive setting, 108 incident cases of decompensated cirrhosis, 46 incident cases of HCC, and 26 liver transplants will be avoided over the lifetime horizon of the model. Discounted costs, discounted outcomes, and incremental cost-effectiveness results are presented in Table 5 . In both the treatment-naive setting and the treatmentexperienced setting, the discounted incremental cost-utility ratio is below AU $20,000/QALY (AU $19,283/QALY in treatment-naive patients and AU $14,948/QALY in treatment-experienced patients). Even though there is no fixed threshold for costeffectiveness in Australia, technologies with a cost/QALY of this magnitude are typically considered to be cost-effective [37] .
Sensitivity Analyses
Sensitivity analyses show the impact of different variables on the ICER. We conducted extensive univariate analyses. Furthermore, multivariate sensitivity analyses were conducted, combining the variables shown to be sensitive in the univariate analyses. Table 6 presents the results of the sensitivity analysis. The model was most sensitive to the annual rates of disease progression (i.e., the Markov transition probabilities), the proportion of patients achieving an SVR, and the utility score given to patients who achieved an SVR. The results from the sensitivity analyses, however, support the cost-effectiveness of telaprevir, with the ICER in the treatment-naive setting varying from AU $1,319 to AU $44,250 per QALY. In the treatmentexperienced setting, the ICER ranged from a situation in which telaprevir plus PR dominated PR alone (discount rate is 0%) to a cost/QALY of AU $34,589 (Markov transition probabilities were the lowest values found in the literature). The range of ICERs in both treatment settings were within the acceptable costeffectiveness range in Australia.
Discussion
Treatment with telaprevir significantly improves the likelihood of achieving an SVR [3, 4] . The results of this study demonstrate that treatment with telaprevir plus PR is expected to result in fewer incident cases of decompensated cirrhosis, HCC, and liver transplants, consequently reducing future health state costs and improving survival. The cost-utility analysis shows that telaprevir plus PR is cost-effective in both the treatment-naive setting and the treatment-experienced setting, with the base-case discounted ICER below AU $20,000/QALY. The sensitivity analysis shows that the results are sensitive to the SVR rates, the Markov transition probabilities, and the utility weights for patients achieving an SVR. The results, however, support the cost-effectiveness of telaprevir, with the incremental cost/QALY below AU $45,000 in all sensitivity analyses in both treatment settings. Given that a probabilistic sensitivity analysis has not been performed, the full extent of the uncertainty surrounding the cost-effectiveness of telaprevir in Australia remains unknown.
As previously discussed, there are four recently published economic evaluations of telaprevir [5] [6] [7] [8] . Only one previous evaluation [8] used the same model structure to estimate the cost-effectiveness of telaprevir in both treatment settings. Note. ICER and ICUR are incremental to PR alone.
ICER, incremental cost-effectiveness ratio; ICUR, incremental cost-utility ratio; LY, life-year; LYG, life-years gained; PR, pegylated interferon plus ribavirin; QALY, quality-adjusted life-year.
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Furthermore, in one of these evaluations [5] , telaprevir treatment was restricted to patients with mild or moderate disease (i.e., patients with cirrhosis were not eligible for treatment). Even though our study differs from these previous evaluations (through the incorporation of the revised categorization of SVR and Australian-specific stopping rules), the results of this study emulate the economic analyses of telaprevir plus PR from other countries [5] [6] [7] , which conclude that telaprevir (and other protease inhibitors) are cost-effective treatments for patients with genotype 1 chronic HCV infection. Our telaprevir model includes three Markov health states to depict the level of fibrosis at baseline (mild fibrosis, moderate fibrosis, and compensated cirrhosis). Of the four previous evaluations of telaprevir, two similarly categorized fibrosis into these three states [5, 7] , whereas Liu et al. [8] used five states (F0, F1, F2, F3, and cirrhosis), as did the Australian budget impact model conducted by the Kirby Institute [16] . The fourth telaprevir study by Camma et al. [6] categorized all precirrhotic patients into one Markov state: chronic HCV [6] . Even though Liu et al. [8] and the Australian Kirby Institute [16] apportioned fibrosis into five Markov states, utility weights in these analyses were either 1) grouped into mild, moderate, and cirrhosis as per our analysis [8] or b) identical for all precirrhotic Markov states (i.e., F0-F3) [16] . In addition, in both studies, the annual costs of care applied were identical across all precirrhotic Markov states. Furthermore, as discussed above, the validation performed by the authors demonstrates that the three-state fibrosis model is consistent with the Australian Kirby Institute model [16] at predicting downstream incidences. Therefore, it appears that the choice of a three-state fibrosis model does not substantially alter the overriding interpretation of the analysis.
In many other models [21] [22] [23] , patients achieving an SVR have the same annual rate of disease progression irrespective of whether they had mild, moderate, or cirrhotic disease before commencing treatment (i.e., patients achieving an SVR were considered to be cured of their virus irrespective of their fibrosis status before treatment). Our model, however, conservatively assumes that patients with cirrhosis achieving an SVR experience disease progression to HCC (albeit at a slower rate than do those who do not achieve an SVR).
This study has several limitations. First, this study was conducted from an Australian health care system perspective. Thus, the analysis does not include indirect costs, such as absenteeism from work or the loss of productivity to employers. The omission of indirect costs is likely to underestimate the economic benefits of telaprevir. Second, the modeled cohort does not include patients with HCV infection who are coinfected with HIV because these patients were not included in the telaprevir randomized controlled trials. These patients are not excluded from reimbursement in Australia. In addition, Markov transition probabilities were assumed to be constant over time. Third, Australian-specific utility weights are not available; therefore, utility weights obtained from studies conducted in other countries were used. Finally, the full extent of the uncertainty surrounding the cost-effectiveness of telaprevir in Australia remains unknown because a probabilistic sensitivity analysis is not required for reimbursement in Australia. As requested in the guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee [38] , univariate and multivariate sensitivity analyses were conducted.
In conclusion, the Markov model demonstrated that the combination of telaprevir plus PR is cost-effective when compared with PR alone in previously untreated and treated patients with genotype 1 chronic HCV infection.
Source of financial support: This article/research was funded by Janssen Australia Pty Ltd. Table 1 ). The lower and upper 95% CI around the incremental SVR rate has been used to estimate the SVR rate for the telaprevir plus PR group. † The range used in the sensitivity analysis is based on the lowest and highest values in the published literature. ‡ Patients with cirrhosis who achieve an SVR can progress to decompensated cirrhosis with an annual probability of 0.0125 (based on odds ratio from Brady et al. [20] ). § In the treatment-naive setting (treatment-experienced setting), patients in both arms of the model have a utility weight of 0.782 (0.710) during the first year.
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